A phase 1 clinical pharmacological study with a single oral dose of KAG-308

Trial Profile

A phase 1 clinical pharmacological study with a single oral dose of KAG-308

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2014

At a glance

  • Drugs KAG 308 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Kaken Pharmaceutical
  • Most Recent Events

    • 27 Mar 2014 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 02 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top